The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3
In this video, Faith Davies, MD, MRCP, MRCPath, FRCPath, NYU Langone, New York, NY, mentions her two top abstracts in multiple myeloma (MM) from the ASH 2025 meeting. This first is the late-breaking abstract outlining the preliminary results from the inMMyCAR trial (NCT07075185), the first-in-human Phase I study of KLN-1010, a novel in vivo gene therapy
generating anti–BCMA CAR-T cells in patients with relapsed/refractory (R/R) myeloma. The second is the results of the MajesTEC-3 trial (NCT05083169), which compared teclistamab plus daratumumab (Tec-Dara) with standard of care regimens in R/R myeloma, yielding unprecedented results. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
